HIV drug Symtuza®▼ receives NHS England funding

The Janssen Pharmaceutical Companies of Johnson & Johnson have announced that NHS England (NHSE) will provide critical funding for Symtuza®▼ (darunavir/cobicistat/emtricitabine/tenofovir alafenamide [D/C/F/TAF]), a once-daily darunavir-based single tablet regimen (STR), for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents aged 12 years and older with a body weight of at least 40 kg.

This means that across England, clinicians will be able to routinely prescribe
D/C/F/TAF to eligible patients with HIV-1. NHS England will routinely commission cobicistat when:

• It is part of the Darunavir/cobicistat/emtricitabine/tenofovir-AF fixed dose combination (FDC) utilised under the tenofovir-AF policy

• It is part of the Darunavir/cobicistat/emtricitabine/tenofovir-AF FDC, used outside the tenofovir-AF policy where there is a multidisciplinary team (MDT)-documented requirement for this regimen and it falls within regional prescribing guidelines

“We are delighted that NHSE has provided vital funding for this treatment option; enabling access for individuals who require a darunavir-based STR to effectively control their HIV”

D/C/F/TAF is the only single tablet regimen indicated for the treatment of this patient group that combines the proven efficacy and durability of darunavir with the potentially improved renal laboratory and bone mineral density profile of F/TAF as compared to F/TDF (emtricitabine/tenofovir disoproxil fumarate). D/C/F/TAF can offer the convenience of an STR alongside the high genetic barrier to resistance provided by darunavir, while being generally well tolerated; genotypic testing should guide use.

Jennifer Lee, Director of Health Economics, Market Access and Reimbursement (HEMAR) and Advocacy at Janssen-Cilag Ltd said, “We are delighted that NHSE has provided vital funding for this treatment option; enabling access for individuals who require a darunavir-based STR to effectively control their HIV, with the potential to support adherence to treatment. This milestone reflects our efforts to help simplify the way in which HIV is treated, supporting people living with HIV to achieve an undetectable viral load while enjoying an improved quality of life. We are thankful for NHSE’s collaboration throughout this process.”